Brief: Vivos Therapeutics Q3 Net Income USD -2.616 Million
14/11/2024 21:05
Nov 14 (Reuters) - Vivos Therapeutics Q3 gross profit USD 2.334 million. * Q3 operating income USD -2.645 million * Q3 operating expenses USD 4.979 million * Q3 basic EPS USD -0.4
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth